Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 May;82(5):186-230.
doi: 10.1016/j.jinf.2020.12.005. Epub 2020 Dec 7.

Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients

Ping-Jen Chen  1 , Chien-Ming Chao  2 , Chih-Cheng Lai  3
Affiliations
Comment

Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients

Ping-Jen Chen et al. J Infect. 2021 May.
No abstract available

Keywords: COVID-19; Favipiravir; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest None to declare.

Figures

Fig. 1
Fig. 1
Forest plot of clinical improvement rate between favipiravir and comparators.
See this image and copyright information in PMC

Comment in

  • Early clinical experience with imatinib in COVID-19: Searching for a dual effect.
    Morales-Ortega A, Rivas-Prado L, Frutos-Pérez B, Jaenes-Barrios B, Farfán-Sedano AI, García-Parra CJ, Hernández-Muniesa B, Duarte-Millán MÁ, Madroñal-Cerezo E, Ontañón-Nasarre A, Ruiz-Giardín JM, Bermejo F, García-Gil M, Gonzalo-Pascua S, San Martín-López JV, Bernal-Bello D. Morales-Ortega A, et al. J Infect. 2021 May;82(5):186-230. doi: 10.1016/j.jinf.2021.02.002. Epub 2021 Feb 5. J Infect. 2021. PMID: 33549625 Free PMC article.

Comment on

References

    1. Saito S., Asai Y., Matsunaga N., Hayakawa K., Terada M., Ohtsu H., et al. First and second COVID-19 waves in Japan: a comparison of disease severity and characteristics. J Infect. 2020 Nov 2:S0163-4453(20)30693-9. - PMC - PubMed
    1. Ivashchenko A.A., Dmitriev K.A., Vostokova N.V., Azarova V.N., Blinow A.A., Egorova A.N., et al. AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a phase II/III multicenter randomized clinical trial. Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa1176. Aug 9;ciaa1176. - DOI - PMC - PubMed
    1. Cai Q., Yang M., Liu D., Chen J., Shu D., Xia J., et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing) 2020 doi: 10.1016/j.eng.2020.03.007. Mar 18. - DOI - PMC - PubMed
    1. Lou Y., Liu L., Yao H., Hu X., Su J., Xu K., et al. Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trial. Eur J Pharm Sci. 2020 doi: 10.1016/j.ejps.2020.105631. Oct 25. - DOI - PMC - PubMed
    1. Udwadia Z.F., Singh P., Barkate H., Patil S., Rangwala S., Pendse A., et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis. 2020 doi: 10.1016/j.ijid.2020.11.142. Nov 16;S1201-9712(20)32453-X. - DOI - PMC - PubMed